DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Jiang LJ, Chau M, Li Y. , et al.
EDP-305, a novel and highly potent farnesoid X receptor agonist, improves liver steatosis, ballooning and non-alcoholic fatty liver disease (NAFLD) activity score (NAS) in a diet-induced murine model of non-alcoholic steatohepatitis.
J Hepatol 2017;
66: S434
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.